Overview

Intranasal Oxytocin for Infants With Prader-Willi Syndrome

Status:
Completed
Trial end date:
2018-01-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the change in suck and swallow competency from baseline to morning of day 6 with intranasal oxytocin spray vs placebo in infants/children with Prader-Willi Syndrome who are in nutritional phase 1a. Videofluoroscopic swallow studies will be performed on treatment day 1 and on the day following treatment morning of day 6.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Florida
Collaborator:
Prader-Willi Syndrome Association
Treatments:
Oxytocin